Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?Zacks Investment Research • 10/09/25
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer TherapyBusiness Wire • 10/09/25
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast DensityBusiness Wire • 10/01/25
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?Zacks Investment Research • 09/26/25
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic DeviceBusiness Wire • 09/22/25
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney DiseasePRNewsWire • 09/15/25
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac ImagingBenzinga • 09/11/25
Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA MoveInvestors Business Daily • 09/11/25
TEM Gains Validation for PurIST Amid Evolving Cancer Care LandscapeZacks Investment Research • 09/11/25
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel DeviceBusiness Wire • 09/11/25